Vaxcyte Closes $1.1B Dual Equity and Convertible Notes Deal
Vaxcyte closed $1.1B in net proceeds through concurrent stock and 1.50% convertible senior notes offerings to finance Phase 3 VAX-31 vaccine development.
biotech financing
Vaxcyte closed $1.1B in net proceeds through concurrent stock and 1.50% convertible senior notes offerings to finance Phase 3 VAX-31 vaccine development.